Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM)

被引：22

作者：

Mateos, M.

Spencer, A.

Taylor, K.

Lonial, S.

De La Rubia, J.

Facon, T.

Bengoudifa, B.

Hazell, K.

Bourquelot, P. M.

San-Miguel, J. F.

机构：

[1] Hosp Univ Salamanca, Salamanca, Spain

[2] Alfred Hosp, Melbourne, Vic, Australia

[3] Haematol Clin Australasia, Brisbane, Qld, Australia

[4] Oncol Clin Australasia, Brisbane, Qld, Australia

[5] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[6] Hosp Univ La Fe, Valencia, Spain

[7] Hop Claude Huriez, Lille, France

[8] Novartis Pharma AG, Basel, Switzerland

来源：

关键词：

D O I：

10.1200/jco.2010.28.15_suppl.8030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8030

引用

页数：2